Conference Day One

08:00

Registration

Federico Pollano
08:50

Opening remarks from the chair

Federico Pollano, Director of Contract Manufacturing and Business Development, Polpharma Biologics
Claudio Albrecht
09:00

Generics market focus

Claudio Albrecht, Former CEO and Chairman of the Board of Directors, Actavis Group, Founder and Managing Partner, Albrecht, Prock & Partners AG
Mazen S Darwazeh
09:30

Successful Strategies to Build New Business, Open up New Markets and Grow Market Share in MENA

Mazen S Darwazeh, Vice Chairman President & CEO MENA & Emerging Markets, Hikma Pharmaceuticals
Panel discussion
10:00

Keynote Panel Discussion: The future of the biosimilar industry - mapping the evolution and development of the biosimilar sector

Mr Sandeep Athalye, Vice President and Head CDMA, Biosimilars, Boehringer Ingelheim
Nitin Naik, Vice President-Global Life Sciences, Frost and Sullivan
Dr Cyrus Karkaria, President - Biotechnology, Lupin Pharma
10:45

Speed networking

11:00

Morning refreshments

Mr Ashwin Pai
11:30

Competitve landscape: forecasting the financial growth of biosimilars in the global healthcare marketplace

Mr Ashwin Pai, Senior Vice President Healthcare Investment Banking, Jefferies International
12:00

Lunch

Frances Cloud
13:30

Peer to peer roundtables

Moderator: Frances Cloud, Founder, Pharmacloud Ltd
Nitin Naik, Vice President-Global Life Sciences, Frost and Sullivan
Dr. Ruth Ellis

Afternoon Chair: Ruth Ellis, Senior Clinical Consultant, Biologics Consulting

Dr. Ruth Ellis, Senior Consultant, Biologics Consulting Group Inc
15:00

Afternoon refreshments

Federico Pollano
15:30

Planning of a biosimilar development project - what to consider from the very beginning

  • Selection
  • Timeline
  • Costs
  • Profitability
Federico Pollano, Director of Contract Manufacturing and Business Development, Polpharma Biologics
Mr Karsten Roth
16:00

Clinical development strategies for biosimilars

Mr Karsten Roth, Head Clinical Operation, Cinfa Biotech GmbH
Dr Steinar Madsen
16:30

Biosimilar Infliximab- experiences and future expectations

Dr Steinar Madsen, Medical Director, Norwegian Medicines Agency, Norway
Nitin Naik
17:00

Promise of Biosimilars- Go to Market Strategies for $27B Chase

  • Market Forecasts for Leading MaB Biosimilars
  • Business Risks/Barriers
  • Stakeholder Analysis & Commercialization Strategies
Nitin Naik, Vice President-Global Life Sciences, Frost and Sullivan

Drinks Reception

last published: 09/Feb/16 16:05 GMT
BOOK NOW